InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,864.67
(
0.40%
)
US TECH 100
19,783.20
(
0.68%
)
Dow Jones
43,275.91
(
0.09%
)
Brent Oil
72.94
(
0.00%
)
Bitcoin
68,751.50
(
0.57%
)
Post# of 253408
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120588
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 151550

Thursday, 11/01/2012 7:37:13 AM

Thursday, November 01, 2012 7:37:13 AM

Post# of 253408

Hard to see if and how GILD will be able to show TAF and its new combo pill is different from Viread's combo - Stribild and will a possible difference in efficacy and or safety would be enough when Viread goes generic?

Even when Viread and Emtriva become generic, Elvitegravir and Cobicstat will still be patent-protected; hence, it may be difficult or impossible for users to configure a 3-pill regimen (branded Elvitegravir + branded Cobicstat + generic Truvada) that is cheaper than Quad Prime, the planned single pill composed of TAF + Truvada + Cobicstat.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up